Why the study?
Hypercoagulation and endothelial dysfunction are central in severe COVID-19, leading to the hypothesis that elevated ANGPT2 promotes hypercoagulation by binding thrombomodulin and inhibiting physiological anticoagulation.
Does elevated Angiopoietin-2 promote hypercoagulation in critically ill COVID-19 patients?
Does elevated Angiopoietin-2 promote hypercoagulation in critically ill COVID-19 patients?
Elevated ANGPT2 levels correlate with hypercoagulation and mortality in severe COVID-19 and inhibit thrombomodulin-mediated anticoagulation, suggesting ANGPT2 inhibition as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Elevated ANGPT2 was associated with hypercoagulability and mortality in COVID-19; leaves open whether inhibition mitigates thrombosis.
Several studies suggest that hypercoagulation and endothelial dysfunction play central roles in severe forms of COVID-19 infections. We hypothesized that the high levels of the inflammatory cytokine Angiopoietin-2 (ANGPT2) reported in hospitalized COVID-19 patients might promote hypercoagulation through ANGPT2 binding to thrombomodulin with resulting inhibition of thrombin/thrombomodulin-mediated physiological anticoagulation. Plasma was collected from critically ill COVID-19 patients treated in the intensive care unit (ICU) at Uppsala University Hospital and ANGPT2 was measured at admission (61 patients) and after ten days (40 patients). ANGPT2 levels were compared with biochemical parameters, clinical outcome, and survival. We found that ANGPT2 levels were increased in COVID-19 patients in correlation with disease severity, hypercoagulation, and mortality. To test causality, we administered ANGPT2 to wildtype mice and found that it shortened bleeding time in a tail injury model. In further support of a role for ANGPT2 in physiological coagulation, bleeding time was increased in endothelial-specific Angpt2 knockout mice. Using in vitro assays, we found that ANGPT2 inhibited thrombomodulin-mediated anticoagulation and protein C activation in human donor plasma. Our data reveal a novel mechanism for ANGPT2 in hypercoagulation and suggest that Angiopoietin-2 inhibition may be tested in the treatment of hypercoagulation in severe COVID-19 infection.
No takes yet. Share an insight, caveat, or question.
Hultström et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: